ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Gross Profit history
Currency unavailable · from the income statement
No Gross Profit data reported for this period type.
Gross Profit vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $73.09M USD | +682.6% | +68.8% | 91.6% | |
| LTM Mar 2026 | $67.34M USD | -34.5% | +110.2% | 93.8% | |
| LTM Mar 2026 | $41.35M USD | -69.4% | -32.2% | 91.2% | |
| LTM Mar 2026 | $28.99M USD | -84.7% | +145.9% | 90.4% | |
| FY2025 | $18.62M USD | — | — | 100.0% | |
| LTM Mar 2026 | €12.06M EUR | -36.4% | +52.2% | 89.7% | |
| LTM Mar 2026 | $612.12K USD | — | -62.8% | 66.4% | |
| LTM Mar 2026 | -$475K USD | -28.7% | — | — | |
| LTM Mar 2026 | -$43.68M USD | -1235.6% | — | 1082.7% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -36.4% | +60.5% | 91.4% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.